08:35 AM EDT, 05/01/2025 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) reported Q1 non-GAAP net loss Thursday of $0.01 per diluted share, narrower than the $0.16 net loss a year earlier.

Analysts polled by FactSet expected a loss of $0.38.

Revenue for the quarter ended March 31 was $594.2 million, up from $494.3 million a year earlier.

Analysts surveyed by FactSet expected $588.4 million.

The company reiterated its full-year 2025 guidance of $2.05 billion to $2.25 billion for total net product revenue, and $650 million to $750 million for net revenue from collaborations and royalties.